Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

Pfizer recorded lower first-quarter revenue on a 75% drop in sales of its Covid-19 treatment, which more than offset growth ...

Pfizer maintained its 2025 guidance but noted it does not include any impact of tariffs or trade policy, “which we are unable ...

Altria's dividend yield is 7%, even as it trades at 11 times estimated earnings over the next 12 months – a 40% premium to ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it maintained a 2025 forecast that does not include potential tariff effects. Sales of ...

New York (AFP) – Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it maintained a 2025 forecast that does not include potential ...

Pfizer said Paxlovid sales fell $1.5 billion, or 75%, to roughly $500 million, partly due to a lower rate of COVID-19 infections in the U.S. and a drop in purchases by governments. To be sure ...